Content area


Chimeric antigen receptor-T-cellebehandling

Klaus Müller1, Marianne Ifversen1, Katrine Kielsen1, Søren Lykke Petersen2, Özcan Met3 & Inge Marie Svane3
1) BørneUngeKlinikken, Rigshospitalet 2) Klinik for Blodsygdomme, Rigshospitalet 3) Nationalt Center for Cancer Immunterapi, Herlev Hospital

Ugeskr Læger 2019;181:V05190309
Ugeskr Læger 2019;181:V05190309
Blad nummer: 

Klaus Müller, Marianne Ifversen, Katrine Kielsen, Søren Lykke Petersen, Özcan Met &
Inge Marie Svane:

Chimeric antigen receptor T-cell therapy

Ugeskr Læger 2019;181:V05190309

Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient’s own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lymphoblastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Larry Højgaard Kristiansen | 11/11
1 Kommentar
af Sven Refslund Poulsen | 09/11
3 kommentarer
af Christian Crüger | 06/11
1 Kommentar
af Anders Christiansen | 05/11
1 Kommentar
af Thamilini Umaramanan | 05/11
2 kommentarer